Gsk Plc · LSE:GSK
Gsk — GlaxoSmithKline — Pictet European Healthcare Conference (April 2004)
18 slides from Gsk's conference presentation, Apr 30, 2004
Slide 1: PICTET European Healthcare Conference
PICTET European Healthcare Conference April 30, 2004
Slide 2: Q1 Performance Summary
Q1 Performance Summary 1Q04 1Q03* % change £m £m CER £ Sales 4,943 5,222 2 (5) - Pharma Sales 4,180 4,466 1 (6) Trading profit 1,562 1,796 (2) (13) Other operating income/(expense) 35 (20) Net interest/(expense) (43) (35) Profit before tax 1,576 1,763 1 (11) Tax rate 27.5% 27.0% Earnings 1,119 1,263
Slide 3: Performance by Operating Division
Performance by Operating Division 1Q04 1Q03 % change £m £m CER Sales Pharmaceuticals 4,180 4,466 1 Consumer Healthcare 763 756 6 Trading Profit Pharmaceuticals 1,451 1,690 (2) Consumer Healthcare 111 106 11
Slide 4: Pharmaceuticals Performance
Pharmaceuticals Performance £m Global US Pharma Sales 4,180 2,093 1% 1% Paxil IR Sales* 190 48 (51%) (77%) Pharma Sales 3,990 2,045 ex-Paxil IR 6% 10% *Excludes Paxil CR sales. % Growth is CER
Slide 5: Key growth drivers of GSK's current portfolio
Key growth drivers of GSK’s current portfolio Respiratory Seretide £581m +22% Diabetes Avandia £238m +18% CNS Lamictal £153m +29% Anti-Viral Valtrex £133m +31% CV Coreg £94m +27% Reported Q104 Global Sales and CER growth
Slide 6: Continued growth in US prescriptions
Continued growth in US prescriptions March MarchNRx NRx 650 +24% +24% 600 550 NRx (000s) 500 450 400 350 300 2 3 3 3 3 3 4 02 02 03 03 03 03 04 03 03 04 02 2 3 t-0 l-0 r-0 t-0 -0 -0 -0 v-0 v-0 p- c- p- c- g- n- n- g- b- n- b- ar ar ay Ju Oc Oc Ap De De Au No No Se Se Au Ja Ja Fe Ju Fe M M M Source:
Slide 7: Advair is 2x more effective than Combivent in reducing breathlessness in COPD
Advair is 2x more effective than Combivent in reducing breathlessness in COPD [1] 3.0 Advair * 2.5 * TDI Score (Improvement in Dyspnea) 2.0 * 1.5 1.0 Combivent 0.5 0.0 Weeks 0 2 4 6 8 [1] Donohue J., et. al. Chest 2003;124:128S *p<0.001 ADVAIR vs Combivent and clinically meaningful difference (ie.,
Slide 8: New indication set to drive share in Paediatricians
New indication set to drive share in Paediatricians >4yrs Advair share of controller market within specialty Approved 22/4/04 27% Primary Care 15% Paediatrician 0% 5% 10% 15% 20% 25% 30% Source: Verispan SPA. Share of Asthma/COPD Controller Market within Specialty (February 2004)
Slide 9: Recent large study shows majority of asthma patients are uncontrolled
Recent large study shows majority of asthma patients are uncontrolled Assessment of 59,538 patients (Typical GP patient population) 73% 24% Controlled Uncontrolled Source: Tricore Market Research May 2002-Dec 2003. 1561 (3%) patients were classified undetermined. Uncontrolled defined as asthma sympt
Slide 10: Avandia/Avandamet
12% Avandia/Avandamet Weekly NRx OAD Market Share 11% • Q104: £238m +18% • GSK’s No. 2 franchise with big Avandamet opportunities to come: launched 10% – ’04 Avandaryl launch Generic metformin ER launched – ’05 psoriasis filing – ’06 outcome studies report 9% Actos 8% 09-02 12-02 03-03 06-03 09-03 1
Slide 11: Bipolar indication drives growth
Bipolar indication drives growth March 75 NRx +67% Month NRX growth % versus prior year 65 55 Bipolar Approval 45 35 25 Apr-03 May-03 Jun-03 Jul-03 Aug-03 Sep-03 Oct-03 Nov-03 Dec-03 Jan-04 Feb-04 Mar-04 Source: Scott Levin NRx monthly AED Market
Slide 12: Great data drives performance
Great data drives performance Q104 £94m +27% (March NRx +48%) – Secondary endpoints presented at ACC Feb 04. Coreg vs Metoprolol: • 20% reduced risk of death from CV event • 30% reduced risk of heart attack • 67% reduced risk of death from stroke – Promotional materials updated Mar 04 Source: Verisp
Slide 13: New Transmission claim & DTC helps drive US sales growth
New Transmission claim & DTC helps drive US sales growth: +38% 135,000 130,000 Rolling 4 week TRx retail volume 125,000 120,000 115,000 110,000 24/01/2003 24/03/2003 24/05/2003 24/07/2003 24/09/2003 24/11/2003 24/01/2004 24/03/2004 Source: Scott Levin TRx weekly anti-herpetic market
Slide 14: Wellbutrin: generic erosion
Wellbutrin: generic erosion US % TRx share of total branded and generic Wellbutrin SR/XL 100% 1% 5% 10% 24% Other generics 65% 60% 51% 43% Watson generic 80% 13% Branded SR 100 & 60% 13% 150mg Branded SR 200mg 6% 6% 40% 7% 7% 41% 44% Wellbutrin XL 8% 37% 32% 20% 27% 0% Dec-03 Jan-04 Feb-04 Mar-04 Wk
Slide 15: Wellbutrin XL uptake and physician satisfaction
• Already used by more than half a million patients • >70% of physicians more satisfied with Wellbutrin XL compared to previous brand used • 75% top 20 managed care plans have Wellbutrin XL at tier 2 • 48 States have Wellbutrin on Medicaid formulary
Slide 16: Pipeline - Outlook for 2004
Pipeline - Outlook for 2004 Advair Pediatric Epivir/Ziagen Avandaryl Vesicare Fraxiparine* Arixtra* Launches/acquisitions *Conditional on completion of Sanofi-Aventis merger
Slide 17: Pipeline - Outlook for 2004
Pipeline - Outlook for 2004 Boniva Advair alvimopan Pediatric Epivir/Ziagen Requip (RLS) 406381 Avandaryl Nelarabine dual Cox-2 inhib. 685698 Vesicare Boostrix allergic rhinitis 363162 Fraxiparine* Priorix Tetra (EU) depression 572016 Arixtra* Rotarix (Lat Am) dual kinase inhib. Launches/acquisition
Slide 18: Slide 18
GlaxoSmithKline — Pictet European Healthcare Conference (April 2004) on 6ix